Argent BioPharma (ASX:RGT) has marked a significant commercial step forward with the arrival of its largest-ever shipment of CannEpil in Ireland, signalling both expanding European market traction and the company’s growing operational scale.

Tetratherix (ASX:TTX) has released its half-year results for the 2026 financial year, with management saying the business remains on track across operations, finances and research as it moves from a research-focused company toward commercial growth.

Australia’s life sciences sector is set for a stronger, more coordinated innovation pipeline following a new national partnership between industry body AusBiotech and biomedical venture creator Proto Axiom.

Australia’s medical technology sector will take centre stage in May when AusBiotech brings its flagship AusMedtech conference to Perth for the first time.

CSL has taken another step in its push to expand its portfolio of innovative therapies, announcing a new licensing agreement with Eli Lilly that could broaden the future reach of its monoclonal antibody candidate, clazakizumab.

Medical Developments International (ASX:MVP) has reported a steady first-half performance for the financial year 2026, with growth in its flagship pain relief product helping to underpin revenue and cash flow despite softer conditions in its respiratory business.

Telix Pharmaceuticals (ASX:TLX) has taken another step in expanding its neuro-oncology portfolio, announcing the submission of a European marketing authorisation application for its brain cancer imaging candidate TLX101-Px.

Nyrada (ASX:NYR) has confirmed growing clinical momentum, strengthening finances, and expanding scientific validation for its lead candidate, Xolatryp, as the company positions itself for its next phase of development.

Australian pharmaceutical manufacturer IDT says it is beginning to show tangible signs of recovery after a period of leadership change and financial pressure, reporting improved earnings and renewed operational momentum in the first half of the financial year 2026.

Percheron Therapeutics (ASX:PER) is positioning itself as a small but strategically focused biotechnology company seeking to carve out a role in the rapidly expanding immuno-oncology market.

The life sciences sector will come together in March 2026 for a major show of support for women’s leadership, as AusBiotech and Medicines Australia expand their partnership to deliver both the long-running Women in Life Sciences Luncheon and, for the first time, a dedicated Leadership Summit.

Botanix Pharmaceuticals (ASX:BOT) has taken a major step to strengthen its commercial momentum and long-term manufacturing strategy, securing commitments for approximately $45 million in fresh capital as it looks to expand production, stabilise supply and accelerate growth of its lead dermatology product, Sofdra.

Remuneration for board directors in Australia’s listed healthcare and biotechnology sector increased materially in the financial year 2025, with growth driven largely by the expanding use of equity-based incentives rather than increases in base fees, according to a new sector analysis by specialist executive and board search firm Wexford Hayes.

Chimeric Therapeutics has strengthened its leadership, appointing experienced biotechnology executive Dr Bradley Glover as Non-Executive Director and Chair, and naming a new Chief Financial Officer, as part of a broader governance refresh.

A new prostate cancer imaging technology from Clarity Pharmaceuticals (ASX:CU6) is showing promise in improving the detection of recurrent disease, after results from a comparative clinical study indicated it may outperform the current standard of care.

Emyria’s (ASX:EMD) push to scale its insurer-backed mental health services across Australia has taken a significant step forward, with Medibank expanding its funding agreement to support patients at the company’s new Mornington Peninsula clinic in Victoria.

CSL has reported a slip in first-half results for 2026, shaped by policy headwinds, restructuring charges and asset impairments, even as the company accelerates a wide-ranging transformation aimed at restoring growth and long-term value.

The therapeutic antibody developer Patrys (ASX:PAB) has announced the appointment of Dr Samantha South as its new Chief Executive Officer, effective 16 February 2026.